RxDoctor Payments Data

Alan Chous

Optometrist · Tacoma, WANPI 1851391866

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 51.2% of the total. Reporting peaked in 2019 at $42,810 and has fallen 77.0% since, to $9,848 in 2025. Among optometrist clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,788in general payments, 2019–2025

Across 198 payments — averaging $579.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$59K
  • LKC Technologies, Inc.$22K
  • Carl Zeiss Meditec, Inc.$11K
  • Regeneron$8K
  • Genentech USA, Inc.$7K
  • Apellis Pharmaceuticals, Inc.$5K
  • plus $3K from 7 others
$12,673in research payments, 2019–2025

Across 5 payments — averaging $2534.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$13K

What the payments were for

  • Consulting fees$32,74829%
  • Speaking & faculty fees$59,20652%
  • Travel & lodging$18,65416%
  • Food & beverage$3,7473%
  • Education$4000%
  • Gifts$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,788 in reported general payments places this provider in the 95th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$32,140
Medicare patients
171
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost78$1,775
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$412
Timolol Maleate22$307

Paid to pharmacies, not to this prescriber.

Other optometrist in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →